JosephEKissMD
Hematology • Pittsburgh, PAAssociate Professor, Medicine, University of Pittsburgh School of Medicine
Dr. Kiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
# Upmc
Pittsburgh, PA 15232Phone+1 412-692-4724
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1982 - 1985
UPMC Medical EducationResidency, Internal Medicine, 1978 - 1981
Georgetown University School of MedicineClass of 1978
Certifications & Licensure
PA State Medical License 1979 - 2024
IL State Medical License 2001 - 2023
VA State Medical License 2013 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- American Board of Pathology Blood Banking
Clinical Trials
- Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study) Start of enrollment: 2008 Jan 01
- Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2009 Apr 01
- Initial Treatment of Patients With Immune Thrombocytopenic Purpura Start of enrollment: 2010 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura.Jennifer M Jones, Alesia Kaplan, Irina Chibisov, Janine Then, Enrico M Novelli
Annals of Hematology. 2024-11-01 - 4 citationsOptimizing interpretation of survival studies of fresh and aged transfused biotin-labeled RBCs.Albert D Donnenberg, Daniel B Kim-Shapiro, Tamir Kanias, Linda R Moore, Joseph E Kiss
Transfusion. 2023-01-01 - 11 citationsCD4T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-α/Tumor Necrosis Factor Receptor 1-Dependent.Iulia Popescu, Mark E Snyder, Carlo J Iasella, Stefanie J Hannan, Ritchie Koshy
American Journal of Respiratory and Critical Care Medicine. 2022-06-15
Press Mentions
Pulling Back the Curtain: Glaivy Batsuli, MDSeptember 1st, 2021
Zika Virus Affecting Blood DonationFebruary 4th, 2016
Iron Supplementation Improves Hemoglobin Recovery Time Following Blood DonationFebruary 10th, 2015- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
